Though the FTC concluded that Sanofi-Aventis violated filing requirements of the 2003 Medicare Prescription Drug, Improvement, and Modernization Act (“MMA”), the agency has closed the investigation and offered its reasoning in...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information: